In Vivo Intraocular Distribution and Safety of Periocular Nanoparticle Carboplatin for Treatment of Advanced Retinoblastoma in Humans

Kalita, Dhrubajyoti; Shome, Debraj; Jain, Aakanksha; Chadha, Kirti; Bellare, Jayesh

doi:10.1016/j.ajo.2014.01.027

Cited by 42 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the majority of recent clinical trials documented by the literature concern liposomal and polymeric nanoparticulate formulations: liposome-based ocular topical therapy has been studied in 72 patients affected by seasonal allergic rhinoconjunctivitis [119] and in 73 patients for the symptomatic treatment of dry eye, with encouraging results [120]; liposomallyentrapped ganciclovir was used for intravitreal injections in 5 AIDS patients suffering cytomegalovirus, increasing the time period required for reinjections [121]; an increased trans-scleral transport of carboplatin-loaded polymethylmethacrylate nanoparticles, without any associated short-term side effects was documented after posterior subtenon injection in 6 patients affected by advanced retinoblastoma [122].…”

Section: Delivery To the Posterior Segment Of The Eyementioning

confidence: 97%

Application of lipid nanoparticles to ocular drug delivery

Battaglia

Serpe

Foglietta

et al. 2016

Expert Opinion on Drug Delivery

127

View full text Add to dashboard Cite

Although eye drops are widely used as drug delivery systems for the anterior segment of the eye, they are also associated with poor drug bioavailability due to transient contact time and rapid washout by tearing. Moreover, effective drug delivery to the posterior segment of the eye is challenging, and alternative routes of administration (periocular and intravitreal) are generally needed, the blood-retinal barrier being the major obstacle to systemic drug delivery. Areas covered: Nanotechnology, and especially lipid nanoparticles, can improve the therapeutic efficiency, compliance and safety of ocular drugs, administered via different routes, to both the anterior and posterior segment of the eye. This review highlights the main ocular barriers to drug delivery, as well as the most common eye diseases suitable for pharmacological treatment in which lipid nanoparticles have proved efficacious as alternative delivery systems. Expert opinion: Lipid-based nanocarriers are among the most biocompatible and versatile means for ocular delivery. Mucoadhesion with consequent increase in pre-corneal retention time, and enhanced permeation due to cellular uptake by corneal epithelial cells, are the essential goals for topical lipid nanoparticle delivery. Gene delivery to the retina has shown very promising results after intravitreal administration of lipid nanoparticles as non-viral vectors.

show abstract

Section: Delivery To the Posterior Segment Of The Eyementioning

confidence: 97%

Application of lipid nanoparticles to ocular drug delivery

Battaglia

Serpe

Foglietta

et al. 2016

Expert Opinion on Drug Delivery

127

View full text Add to dashboard Cite

show abstract

“…Non-viral drug delivery-based nanoparticle systems are preferable routes for administration of ophthalmic drugs because of safety concerns. Recently, polymethylmethacrylate nanoparticles loaded with the chemotherapeutic drug carboplatin have been tested for their efficacy in patients suffering from intraocular retinoblastoma, a cancer of the retina [115]. Increased transportation of nanoparticle-based carboplatin across the sclera to the ocular tissue was observed in patients with a sustained release of the chemotherapeutic drug from nanoparticles.…”

Section: Nanoparticles For Ophthalmic Deliverymentioning

confidence: 99%

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Ponnappan

Chugh

2015

Pharm Med

View full text Add to dashboard Cite

Nanotechnology-based pharmaceutics is a fast emerging field in the diagnosis and therapy of a number of human diseases, including cancer. Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. They have been investigated for drug delivery to different tumor tissues, to brain where the blood-brain barrier poses a significant problem in the delivery of effective therapeutic molecules, to ocular tissues and also for eliciting immune response via delivery of vaccines. Particularly, the small size of nanoparticles facilitates their easy access to a wide range of cells and tissues. Further, the size of nanoparticles can be controlled and their surface can be modified with desired ligands and receptors to specifically target cells of interest as well as achieve controlled drug release. Research is being carried out on numerous biological and synthetic nanoparticles. Diverse strategies are being developed to improve their stability, specificity and drug delivery efficiency. Nanoparticles have been also used in conjunction with cellpenetrating peptides for efficient drug delivery. Cellpenetrating peptides serve as efficient nanocarriers owing to their inherent ability to cross the plasma membrane barrier and deliver cargo to intracellular targets. Modification of nanoparticles with cell-penetrating peptides further increases their efficacy for increased permeation into varied cells and tissues. The current review focuses on different classes of nanoparticles and their application in the treatment of several types of diseases. Key PointsNanoparticle-based therapeutic drugs are widely used for the treatment of a number of diseases, including cancer.Ease of modulation of size and tuning of the nanoparticles with various ligands make them effective for formulation into specific drugs with increased therapeutic index and reduced toxicity.Successful pre-clinical and early phase clinical trials have promised the emergence of nanocarrier-based drugs.

show abstract

“…The advantage of local administration is the limited area of action for highly active drugs. Thus, ocular administration of polymethylmetacrylate NP containing carboplatin, a chemotherapy drug with adverse side effects, allow a sustained-release of the drug in the vitreous and the retina without systemic detection of the drug for retinoblastoma treatment after a single subtenon injection [77]. Amongst local targets can be cited the inner ear [80] and hair follicles [81].…”

Section: Administration Routes For Therapy With Npsmentioning

confidence: 99%

“…Moreover, some organs are more easily accessible by another way than a systemic route. This is the case in the eyes where NP-loaded drugs or gene-delivery systems can be delivered by instillation into the conjunctival sac, intravitreous or subtenon injections of NPs that were set up for the treatment of eye diseases such as retinal neurodegeneration [73], glaucoma [74,75], virus-infection [76] or retinoblastoma [77]. Another example is the rectal administration that is used for colorectal cancer therapy purpose [78] but also for delivery of anti-vomiting drugs as an complement of chemotherapy [79].…”

Section: Administration Routes For Therapy With Npsmentioning

confidence: 99%